Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18594642 | 0.85 | HCRTR1 (0.42) | HCRTR1HCRTR2OPRK1TRPM8PLK1 | |
| SCHEMBL20911215 | 0.85 | NPC1 (0.48) | HCRTR1HCRTR2TRPM8PLK1L3MBTL1 | |
| SCHEMBL17069771 | 0.83 | HCRTR1 (0.41) | HCRTR1HCRTR2OPRK1TRPM8PLK1 | |
| SCHEMBL20169441 | 0.82 | HCRTR1 (0.40) | HCRTR1HCRTR2OPRK1TRPM8PLK1 | |
| SCHEMBL17723708 | 0.77 | NPC1 (0.48) | HCRTR1HCRTR2TRPM8PLK1L3MBTL1 | |
| SCHEMBL17071972 | 0.77 | HCRTR1 (0.42) | HCRTR1HCRTR2OPRK1TRPM8PLK1 | |
| SCHEMBL18163368 | 0.76 | HCRTR1 (0.46) | HCRTR1HCRTR2L3MBTL1 | |
| SCHEMBL16856594 | 0.75 | L3MBTL1 (0.47) | OPRK1TRPM8L3MBTL1S1PR1GABRG2 | |
| SCHEMBL14363624 | 0.75 | L3MBTL1 (0.47) | OPRK1TRPM8L3MBTL1S1PR1GABRG2 | |
| SCHEMBL27481642 | 0.75 | CHRNA7 (0.45) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586950-B2 | 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160304490-A1 | 2-PYRIDYLOXY-3-ESTER-4-ETHER OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20150252033-A1 | 2-PYRIDYLOXY-3-ESTER-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252033-A1 | 2-PYRIDYLOXY-3-ESTER-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NTSR2 | HCRTR1 2/4885HCRTR2 1/4885OPRK1 81/4885 |
| US-20160304490-A1 | 2-PYRIDYLOXY-3-ESTER-4-ETHER OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | HCRTR1 2/4885HCRTR2 1/4885OPRK1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.